ArticleIranian journal of biotechnology2025
Biotechnological Insights into KAT2A-Mediated Epigenetic Regulation in Colorectal Cancer: A Transcriptomic and Functional Genomics Approach.
Article in Iranian journal of biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Epigenetic modifiers such as lysine acetyltransferase 2A (KAT2A) have been reported to be the key regulators of gene expression in various cancers, including colorectal cancer (CRC). The transcriptomic effect of Objectives: The objective of this research was to investigate genome-wide transcriptional alterations induced by Materials and Methods: KAT2A-knockout HCT116 cell high-throughput RNA sequencing data (GSE246881) were analyzed. Differentially expressed genes (DEGs) were defined by DESeq2. Functional enrichment analysis, including Gene Ontology (GO) and KEGG pathways, and protein-protein interaction (PPI) network building were performed using integrated bioinformatics tools. Results: Conclusion: KAT2A plays a pivotal role in oncogenic signaling pathways in CRC. The identified genes and pathways here present promising prospects for biotechnological application in cancer biomarker identification and targeted therapy, demonstrating the potential of KAT2A-centered regulatory networks in guiding CRC management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.